Back to search

Article

A nasal vaccine candidate, based on S2 and N proteins from SARS-CoV-2, generates a broad antibody response systemic and at lower respiratory tract

2025-05-09

Abstract excerpt

Since the beginning of the COVID-19 pandemic various groups around the world have intensively worked in the development of vaccine candidates against SARS-CoV-2. Several vaccines have been approved in the past years, the majority are based on the Spike or RBD proteins and employs parenteral administration routes. Considering the recent history of Coronavirus zoonotic events, causing serious human health problems,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b98daead-0aa4-5cb0-8fff-a30512f38cfd
DOI
10.1101/2025.05.09.653001
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A nasal vaccine candidate, based on S2 and N proteins from SARS-CoV-2, generates a broad antibody response systemic and at lower respiratory tractDOI 10.1101/2025.05.09.653001
Immunological evaluation in African Green Monkeys of two nasal vaccine candidates to induce a broad immunity against coronavirusesSemantic proximity
Immunogenicity and in vivo protective effects of recombinant nucleocapsid-based SARS-CoV-2 vaccine Convacell®Semantic proximity
Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of ConcernsSemantic proximity
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathologySemantic proximity
Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron VOCsSemantic proximity
The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine VectorSemantic proximity
The protective nasal boosting of a triple-RBD subunit vaccine against SARS-CoV-2 following inactivated virus vaccinationSemantic proximity
Active and Passive Immunization of Syrian Hamsters with An Attenuated SARS-CoV-2 Protects against New Variants of ConcernSemantic proximity
A live attenuated influenza virus-vectored intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2 infectionSemantic proximity
Repurposing NASVAC, a hepatitis B therapeutic vaccine, for pre- and postexposure prophylaxis of SARS-CoV-2 infectionSemantic proximity
Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccinationSemantic proximity
A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamstersSemantic proximity
Select a neighboring publication to make it the new centre.